SAN RAFAEL, Calif. (TheStreet) -- The biotech takeout rumor of the day has Roche (RHHBY) lining up $15 billion in financing to acquire BioMarin Pharmaceuticals (BMRN), according to a report by DealReporter.
Who knows if such a deal will really happen -- Roche is actually denying the financing report -- but takeout interest in BioMarin makes more sense than the similar rumor floated last July in which Roche was readying a buyout offer for Alexion Pharmaceuticals (ALXN).
With BioMarin, Roche would get a more diversified orphan drug business. BioMarin brought in $500 million in revenue last year from four drugs that treat rare, life-threatening disorders. BioMarin has a fifth orphan disease drug, Vimizim, which is likely receive FDA approval early next year. Three additional orphan disease drugs are still in clinical trials. BioMarin is also developing a PARP inhibitor for breast and ovarian cancer.
Cancer is Roche's sweet spot, so the opportunity to pick up a company with a proven track record of orphan drug development and a cancer drug as a bonus might prove irresistible.Deutsche Bank analyst Robyn Karnauskas pegs "fair value" for BioMarin at around $92 per share in a takeover scenario, or roughly $13 billion. Simplistically, Roche could be getting more bang for its buck by paying $13 billion for BioMarin, although that's still a lot of money to pay for a company which still isn't profitable. Cost synergies in a Roche-BioMarin deal may not be great given the lack of overlap in research and development and marketing. Roche doesn't have an existing orphan drug business. But a $13 billion price tag values BioMarin at 26 times sales, which is expensive. (BioMarin revenue could double or more in the next few years, so the deal may actually be less expensive.) Still, if Roche were to pay $25 billion for Alexion (the rumored price tag back in July), that's 19-20 times sales. Cheaper, perhaps, although the knock on the rumored Alexion deal is that Roche would essentially be spending all that money for a single orphan drug, albeit one used to treat multiple diseases. All stuff to think about.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV